Endonovo Therape Financials

ENDV

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2023 Currency USD FYE December

This page shows Endonovo Therape (ENDV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENDV FY2022 2026-04-22

High reported gross margin does not offset tiny revenue scale, leaving Endonovo reliant on external funding to keep operating.

From FY2021 to FY2022, cash nearly disappeared from $85.9K to $0 while financing inflows of $593.0K still failed to cover -$678.8K of operating cash burn; that helps explain why shares outstanding jumped from 72.0M to 194.3M even though revenue was only $135.4K. The business is being funded more by recapitalization than by customers.

Gross margin stayed high at 92.6% in FY2022, but that produced only $125.4K of gross profit against an operating loss of -$3.3M. Similar margins in prior years show the core constraint is not direct product cost; it is the inability to spread corporate costs across meaningful revenue.

Liquidity is exceptionally thin: FY2022 ended with just $15.8K of current assets against $33.4M of current liabilities, and total liabilities rose from $17.8M to $33.5M while total assets fell to $1.3M. That leaves the balance sheet shaped by accumulated obligations rather than liquid resources or retained operating cash.

Financial Health Signals

Financial Profile 20/100

Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Endonovo Therape's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Endonovo Therape has an operating margin of -2411.7%, meaning the company retains $-2412 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -3045.7% the prior year.

Growth

Endonovo Therape's revenue surged 85.2% year-over-year to $135K, reflecting rapid business expansion. This strong growth earns a score of 17/100.

Leverage

100

Endonovo Therape carries a low D/E ratio of -0.22, meaning only $-0.22 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Endonovo Therape's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

2/9

Endonovo Therape passes 2 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Interest Coverage At Risk

-2.5x

Endonovo Therape earns $-2.5 in operating income for every $1 of interest expense (-$3.3M vs $1.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$135K

YoY+85.2%

10Y CAGR+16.0%

Endonovo Therape generated $135K in revenue in fiscal year 2022. This represents an increase of 85.2% from the prior year.

EBITDA

-$2.6M

YoY-65.9%

Endonovo Therape's EBITDA was -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 65.9% from the prior year.

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$98

YoY-99.9%

5Y CAGR-74.5%

10Y CAGR-18.9%

Endonovo Therape held $98 in cash against $7.2M in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

194M

YoY+169.8%

Endonovo Therape had 194M shares outstanding in fiscal year 2022. This represents an increase of 169.8% from the prior year.

Margins & Returns

Gross Margin

92.6%

YoY+13.1pp

Endonovo Therape's gross margin was 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is up 13.1 percentage points from the prior year.

Operating Margin

-2411.7%

YoY+634.0pp

Endonovo Therape's operating margin was -2411.7% in fiscal year 2022, reflecting core business profitability. This is up 634.0 percentage points from the prior year.

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ENDV Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$135K+85.2%	$73K-55.9%	$166K-46.5%	$310K+272.5%	$83K	N/A
Cost of Revenue	$10K-33.3%	$15K-77.1%	$65K-30.0%	$93K+622.2%	$13K	N/A
Gross Profit	$125K+115.7%	$58K-42.1%	$100K-53.7%	$217K+208.2%	$70K	N/A
R&D Expenses	N/A	$0-100.0%	$3K-97.9%	$153K-44.2%	$274K+138.2%	$115K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$3.3M-46.6%	-$2.2M+23.5%	-$2.9M+23.5%	-$3.8M+8.4%	-$4.2M+9.7%	-$4.6M
Interest Expense	-$1.3M-240.4%	$942K-54.8%	$2.1M+12153.4%	$17K+100.3%	-$5.2M+10.2%	-$5.8M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.1M-684.9%	-$396K	N/A	-$6.4M+40.5%	-$10.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Revenue	$2K-96.6%	$45K-48.4%	$88K-27.9%	$121K+1008.2%	$11K+1586.2%	$650-71.5%	$2K+622.2%	$316
Cost of Revenue	$827	N/A	$4K-17.9%	$5K+20.8%	$4K+951.4%	$383-46.4%	$714-91.9%	$9K
Gross Profit	$693-98.5%	$45K-45.9%	$84K-28.3%	$117K+1581.8%	$7K+2496.6%	$267-83.0%	$2K+118.3%	-$9K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$473K+58.2%	-$1.1M-113.7%	-$529K-9.6%	-$483K+2.8%	-$497K+72.4%	-$1.8M-270.3%	-$486K-30.0%	-$374K
Interest Expense	-$286K+8.6%	-$313K-1.1%	-$309K0.0%	-$309K+8.6%	-$339K-0.3%	-$338K-0.4%	-$336K-120.3%	$1.7M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$766K-137.1%	$2.1M	N/A	N/A	-$603K+76.1%	-$2.5M-4.7%	-$2.4M-200.7%	$2.4M
EPS (Diluted)	$0.00+100.0%	$-0.01	$0.00	N/A	$0.00+100.0%	$-0.02+33.3%	$-0.03	N/A

ENDV Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$1.3M-36.2%	$2.0M-23.0%	$2.6M-20.4%	$3.3M-22.8%	$4.2M-8.0%	$4.6M
Current Assets	$16K-83.3%	$95K+105.4%	$46K-26.2%	$63K-83.6%	$382K+244.1%	$111K
Cash & Equivalents	$98-99.9%	$86K+540.4%	$13K-29.0%	$19K-95.0%	$379K+320.5%	$90K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$944+0.2%	$942-95.9%	$23K+579.9%	$3K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$33.5M+88.2%	$17.8M+4.7%	$17.0M-28.6%	$23.8M+52.1%	$15.6M+10.4%	$14.2M
Current Liabilities	$33.4M+88.6%	$17.7M+5.2%	$16.8M-28.8%	$23.6M+52.6%	$15.5M+15.4%	$13.4M
Long-Term Debt	$7.2M-1.4%	$7.3M+6.2%	$6.8M-0.6%	$6.9M-15.7%	$8.2M+10.9%	$7.4M
Total Equity	-$32.2M-104.0%	-$15.8M-9.7%	-$14.4M+29.9%	-$20.5M-80.0%	-$11.4M-19.3%	-$9.6M
Retained Earnings	-$75.1M-33.1%	-$56.4M-5.8%	-$53.3M-0.8%	-$52.9M-48.6%	-$35.6M-22.1%	-$29.2M

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Total Assets	$816K-19.6%	$1.0M-15.4%	$1.2M-6.4%	$1.3M-11.7%	$1.5M-9.0%	$1.6M-12.1%	$1.8M-9.6%	$2.0M
Current Assets	$36K-51.3%	$73K-23.5%	$95K+501.5%	$16K-34.3%	$24K+305.1%	$6K-90.8%	$64K-32.1%	$95K
Cash & Equivalents	$0-100.0%	$33K+198.0%	$11K+11065.3%	$98-99.6%	$23K	$0-100.0%	$60K-30.2%	$86K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$3K	N/A	$944-0.1%	$9450.0%	$945+0.1%	$944
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.8M+1.5%	$23.4M-8.4%	$25.6M-23.6%	$33.5M+58.9%	$21.1M+1.5%	$20.8M+4.5%	$19.9M+11.6%	$17.8M
Current Liabilities	$23.7M+2.4%	$23.1M-9.2%	$25.5M-23.6%	$33.4M+59.1%	$21.0M+1.5%	$20.7M+4.6%	$19.8M+11.7%	$17.7M
Long-Term Debt	$7.1M+0.5%	$7.1M+2.2%	$6.9M-3.5%	$7.2M-1.6%	$7.3M-1.9%	$7.4M+0.7%	$7.4M+1.3%	$7.3M
Total Equity	-$23.0M-2.4%	-$22.4M+8.0%	-$24.4M+24.3%	-$32.2M-64.1%	-$19.6M-2.3%	-$19.2M-6.2%	-$18.0M-14.3%	-$15.8M
Retained Earnings	-$66.6M-1.2%	-$65.9M+3.0%	-$67.9M+9.6%	-$75.1M-21.2%	-$62.0M-1.0%	-$61.4M-4.3%	-$58.9M-4.3%	-$56.4M

ENDV Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$679K+31.2%	-$987K-33.0%	-$742K+70.8%	-$2.5M+11.7%	-$2.9M+3.7%	-$3.0M
Capital Expenditures	N/A	N/A	N/A	$3K-71.1%	$9K	N/A
Free Cash Flow	N/A	N/A	N/A	-$2.5M+11.9%	-$2.9M	N/A
Investing Cash Flow	N/A	N/A	N/A	-$3K+71.1%	-$9K+99.7%	-$3.0M
Financing Cash Flow	$593K-44.0%	$1.1M+43.9%	$736K-66.3%	$2.2M-31.3%	$3.2M-47.3%	$6.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Operating Cash Flow	-$65K+60.6%	-$166K+4.2%	-$173K+23.2%	-$226K-82.1%	-$124K+40.0%	-$206K-67.9%	-$123K+68.6%	-$391K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$33K-82.5%	$188K+1.9%	$184K-9.1%	$203K+37.8%	$147K+0.3%	$147K+51.0%	$97K-79.4%	$472K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENDV Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	92.6%+13.1pp	79.5%+18.9pp	60.6%-9.3pp	69.9%-14.6pp	84.5%	N/A
Operating Margin	-2411.7%+634.0pp	-3045.7%-1289.2pp	-1756.5%-528.4pp	-1228.1%+3767.3pp	-4995.3%	N/A
Net Margin	N/A	-4247.2%-4008.6pp	-238.6%	N/A	-7729.5%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-154.7%-139.5pp	-15.2%	N/A	-151.7%+82.7pp	-234.4%
Current Ratio	0.000.0	0.010.0	0.000.0	0.00-0.0	0.02+0.0	0.01
Debt-to-Equity	-0.22+0.2	-0.46+0.0	-0.48-0.1	-0.34+0.4	-0.72+0.1	-0.77
FCF Margin	N/A	N/A	N/A	-820.1%+2648.2pp	-3468.3%	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Gross Margin	45.6%-54.4pp	100.0%+4.6pp	95.4%-0.5pp	96.0%+32.7pp	63.3%+22.2pp	41.1%-27.6pp	68.7%+2772.8pp	-2704.1%
Operating Margin	-31105.1%-28602.2pp	-2502.9%-1898.3pp	-604.6%-206.9pp	-397.7%+4135.0pp	-4532.7%+272198.0pp	-276730.6%-255443.9pp	-21286.7%+97002.6pp	-118289.2%
Net Margin	-50405.9%-54971.5pp	4565.6%	N/A	N/A	-5505.1%+383130.4pp	-388635.5%-282885.8pp	-105749.7%-864082.0pp	758332.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-93.9%-297.3pp	203.4%	N/A	N/A	-41.6%+116.8pp	-158.4%-25.4pp	-133.0%-252.3pp	119.4%
Current Ratio	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.01
Debt-to-Equity	-0.310.0	-0.31-0.0	-0.28-0.1	-0.22+0.1	-0.37+0.0	-0.39+0.0	-0.41+0.1	-0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$32.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Globestar Therapeutics Corp GSTC

$124K

Tracon Pharmaceu TCON

$4.3M

Trevena Inc TRVN

$1.3M

Scorpius Holdings SCPX

$1.5M

Vincerx Pharma Inc VINC

$3.5M

Frequently Asked Questions

What is Endonovo Therape's annual revenue?

Endonovo Therape (ENDV) reported $135K in total revenue for fiscal year 2022. This represents a 85.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Endonovo Therape's revenue growing?

Endonovo Therape (ENDV) revenue grew by 85.2% year-over-year, from $73K to $135K in fiscal year 2022.

What is Endonovo Therape's EBITDA?

Endonovo Therape (ENDV) had EBITDA of -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Endonovo Therape have?

As of fiscal year 2022, Endonovo Therape (ENDV) had $98 in cash and equivalents against $7.2M in long-term debt.

What is Endonovo Therape's gross margin?

Endonovo Therape (ENDV) had a gross margin of 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is Endonovo Therape's operating margin?

Endonovo Therape (ENDV) had an operating margin of -2411.7% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is Endonovo Therape's operating cash flow?

Endonovo Therape (ENDV) generated -$679K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Endonovo Therape's total assets?

Endonovo Therape (ENDV) had $1.3M in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does Endonovo Therape have outstanding?

Endonovo Therape (ENDV) had 194M shares outstanding as of fiscal year 2022.

What is Endonovo Therape's current ratio?

Endonovo Therape (ENDV) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Endonovo Therape's debt-to-equity ratio?

Endonovo Therape (ENDV) had a debt-to-equity ratio of -0.22 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Endonovo Therape's cash runway?

Based on fiscal year 2022 data, Endonovo Therape (ENDV) had $98 in cash against an annual operating cash burn of $679K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Endonovo Therape's debt-to-equity ratio negative or unusual?

Endonovo Therape (ENDV) has negative shareholder equity of -$32.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Endonovo Therape's Piotroski F-Score?

Endonovo Therape (ENDV) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can Endonovo Therape cover its interest payments?

Endonovo Therape (ENDV) has an interest coverage ratio of -2.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Endonovo Therape?

Endonovo Therape (ENDV) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.